GSK sued by inventors of Relenza anti-flu drug
Thursday 06 May 2004
GlaxoSmithKline IS being sued by the Australian inventors of its controversial flu treatment Relenza, who accuse the giant drug maker of failing to properly promote the product.
The Melbourne-based biotech group Biota, which licensed Relenza in 1990 to what was then Glaxo, says it has been driven to the courts after two years of fruitless negotiations with GSK. The product failed to live up to its early promise and had sales last year of less than £10m, despite being approved in 70 countries.
"Relenza was a breakthrough influenza drug that had great potential but it was effectively abandoned at birth," Biota's chief executive, Peter Molloy, said. The company says GSK breached the terms of its licensing deal by failing to launch Relenza in a number of countries, by dropping further studies that may have widened its use, and by not pursuing fully ways to improve the inhaler used for taking the drug. It is demanding unspecified damages, which could total up to $100m (£56m).
GSK said it was surprised by Biota's lawsuit but would not comment further.
The high hopes for Relenza began to falter when the National Institute for Clinical Excellence, the NHS's arbiter of value for money, ruled that the drug would only marginally improve the treatment of flu and should be prescribed only in very limited circumstances. It was a ruling that infuriated Sir Richard Sykes, then chairman of Glaxo Wellcome, so much that he threatened to move the company's headquarters to the US.
Biota is aggrieved that Relenza was sidelined after the merger of Glaxo Wellcome with SmithKline Beecham to create GSK in 2000. GSK has been arguing in private that it pulled applications to launch the drug as a prevention for flu after it became clear it would not get approval in the US.
Relenza was discovered by Biota scientists in 1989 and was the first in a new generation of anti-flu drugs, called neuraminidase inhibitors, which are effective against both major strains of influenza.
However, the fact that it has to be used with an inhaler put it at an immediate disadvantage to a rival pill from Roche, the Swiss pharmaceuticals giant.
Board creates magnetic field to achieve lift
Like Madonna, Sister Cristina Scuccia's video is also set in Venice
Singer says the track was 'force-fed down people's throats'
techThe original free dating app will remain the same, developers say
Endangered species spotted in a creek in the Qinling mountains
Trend which requires crisps, a fork and a strong stomach is sweeping Mexico's streets
Some experiencing postnatal depression don't realise there is a problem. What can be done?
- 3 Drink alcohol and eat meat to improve male fertility - but cut down on coffee, studies suggest
Ukraine crisis: Donetsk 'tactical missile' explosion at factory sends blast wave across rebel-held city
Jack the Ripper: Scientist who claims to have identified notorious killer has 'made serious DNA error'
Oscar de la Renta dead: Legendary US fashion designer dies after long cancer battle aged 82
Banksy arrest hoax: Internet duped by fake report claiming street artist's identity has been revealed
Super-sized ships arrive in Britain: How big can they get?
Cameron is warned 'no possibility' of UK reducing immigration and that bid to bring in quota on migrant workers would be illegal
Residents should throw a street party and mix with immigrant neighbours, councils told
Russell Brand threatened with arrest after filming outside Fox News headquarters
London bus driver 'kicks gay couple off for kissing'
Lord Freud: Tory welfare minister apologises after saying disabled people are 'not worth’ the minimum wage
Lord Freud hangs on as MPs of all parties 'call for his head' over disability comments
iJobs Money & Business
£23000 - £26000 Per Annum: Clearwater People Solutions Ltd: Our client is curr...
£25 - 30k: Guru Careers: A Corporate Actions Administrator / Operations Admini...
£18 - 23k + Benefits: Guru Careers: We are seeking a Customer Service Executiv...
£60 - 65k + Benefits: Guru Careers: We are seeking a ASP.NET Web Developer / ....